A recent study indicates that individuals who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who end conventional diet and exercise programs.
Findings released in a leading health publication points out that while obese individuals frequently drop a large proportion of their total mass while on the medication, the mass returns at an average rate of nearly a kilo each month upon discontinuation.
"Users purchasing these medications should be cognizant of the potential of fast rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb.
This pace of regain suggests a return to starting mass in about one and a half years.
Analyzing Treatments
The study, which examined 37 of studies involving over 9,000 of participants, compared the effects of these new drugs with other pills.
The team point out that individuals who shed pounds through diet and exercise generally experience a slower creep back—around 0.1 kg a month—post-intervention.
Explaining the Fast Rebound
Doctors suggest the way of the injections explains the amplified regain.
These medications imitate a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Artificially providing the hormone levels several times higher than the body's typical production might result in the system to generate a reduced amount of its endogenous hormone, and may also diminish sensitivity to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this hormone supplement results in hunger is unsuppressed, making excessive eating a significant risk."
A Chronic Issue?
Health authorities suggest the injections for people with weight-linked medical conditions, alongside prescribed lifestyle changes.
Professionals contend that, given the high risk of weight regain, the therapy is often life-long.
This perspective is reinforced by drug manufacturers, who note that the findings "underscore the persistent character of excess weight," akin to managing diseases like hypertension.
Patient Accounts
Users who have discontinued the jabs describe a intense return of hunger.
"It felt as if something that goes on and I was suddenly ravenous," said an individual.
This challenge is compounded if patients have not adopted sustainable dietary or behavioural changes during therapy.
Growing Adoption
Survey data suggest that millions of adults in the UK have tried these injections in the past year, with desire being substantial.
- Adoption is more common among women compared to males.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Ultimately, researchers caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone cure and lasting health benefits hinges on ongoing lifestyle support.
